Effects of combined thymosin and hydrocortisone on immune response in septic mice

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 8, 2015, Pages 12989-12994

  Zhang, Daquan ^a   Zhou, Yi ^b   Cheng, Qinghong ^c  

^a PEOPLE S HOSPITAL OF XINJIANG UYGUR AUTONOMOUS REGION   (China)

^b Intensive Care Unit The Eleventh Hospital of PLA   (China)

^c SHIHEZI UNIVERSITY   (China)

Author keywords

Dendritic cells; Hydrocortisone; Immune response; Sepsis; Thymosin

Indexed keywords

CD86 ANTIGEN; HYDROCORTISONE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE RESPONSE; INFLAMMATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SEPSIS; SURVIVAL;

EID: 84943538077     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Moss M and Martin GS. Global perspective on the epidemiology of sepsis. Med 2004; 30: 527-529.
2. Perl M, Chung CS, Carber M, Huang X and Ayala A. Contribution of anti inflammatory/immune suppressive processes to the pathology of sepsis. Front Biosci 2006; 11: 272-299.
3. Goldstein AL, Guba A, Zatz MM, Hardy MA and White A. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci U S A 1972; 69: 1800-1803.
4. Zhang Y, Chen H, Li YM, Zheng SS, Chen YG, Li LJ, Zhou L, Xie HY and Praseedom RK. Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J Infec Dis 2008; 198: 723-730.
5. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM; Surviving Sepsis Campaign Management Guidelines Committee. Surviving sepsis campaign guidelines for management of severe sepsis and sepsis shock. Crit Care Med 2004; 32: 858-873.
6. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P and Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2001; 288: 862-871.
7. Finfer S. Corticosteroids in septic shock. N Engl J Med 2008; 358: 188-190.
8. Bohannon J, Cui W, Cox R, Przkora R, Sherwood E and Toliver-Kinsky T. Prophylactic treatment with fms-like tyrosine kinase-3 ligand after burn injury enhanced global immune responses to infection. J Immunol 2008; 180: 3038-3048.
9. Toliver-Kinsky TE, Cui W, Murphey ED, Lin C and Sherwood ER. Enhancement of dendritic cell production by fms-like tyrosin kinase-3 ligand increases the resistance of mice to a burn wound infection. J Immuol 2005; 174: 404-410.
10. Dubsky P, Ueno H, Piqueras B, Connolly J, Banchereau J and Palucka AK. Human dendritic cell subsets for vaccination. J Clin Immunol 2005; 25: 551-572.
11. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
12. Ding Y, Chung CS, Newton S, Chen Y, Carlton S, Albina JE and Ayala A. Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in mice. Shock 2004; 22: 137-144.
13. Tinsley KW, Grayson MH, Swanson PE, Drewry AM, Chang KC, Karl IE and Hotchkiss RS. Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. J Immonol 2003; 171: 909-914.
14. Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF, Wagner TH, Cobb JP, Coopersmith C and Karl IE. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 2002; 168: 2493-2500.
15. Guisset O, Dilhuydy MS, Thiébaut R, Lefèvre J, Camou F, Sarrat A, Gabinski C, Moreau JF and Blanco P. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med 2007; 33: 148-152.
16. Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Chapman MJ and Lesnik P. Enhanced dendritic cell survival attenuates lipopolysaccharide-induced immunosuppression and increases resistance to lethal endotoxic shock. J Immunol 2008; 180: 6941-6946.
17. Pène F, Zuber B, Courtine E, Rousseau C, Ouaaz F, Toubiana J, Tazi A, Mira JP and Chiche JD. Dendritic cells modulate lung response to pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. J Immunol 2008; 181: 8513-8520.
18. Thomas RC, Bath MF, Stover CM, Lambert DG and Thompson JP. Exploring LPS-induced sepsis in rats and mice as a model to study potential protective effects of the nociceptin/orphanin FQ system. Peptides 2014; 61: 56-60.
19. Mcewan BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS, Goldfarb RH, Kitson RP, Miller AH, Spencer RL and Weiss JM. The role of adrenoconticoids as modulators of immune function in health and disease: neural endocrine and immune interactions. Brain Res Brain Res Rev 1997; 23: 79-133.
20. Bakker JM, Schmidt ED, Kroes H, Kavelaars A, Heijnen CJ, Tilders FJ and van Rees EP. Effects of neonatal dexamethasone treatment on hypothalamo-pituitary adrenal axis and immune system of the rat. J Neuroimmunol 1997; 74: 69-76.
21. Goldstein AL, Guha A, Zatz MM, Hardy MA and White A. Purification and biological activity of thymosin,a hormone of the thymus gland. Proc Natl Acad Sci U S A 1972; 69: 1800-1803.
22. Zhang Y, Chen H, Li YM, Zheng SS, Chen YG, Li LJ, Zhou L, Xie HY and Praseedom RK. Tymosin alpha l- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra -abdominal infection due to carbapenem-resistant bacteria. J Infect Dis 2008; 198: 723-730.
23. Goldstein AL. From lab to beside: Emerging clinical application of thymosin alpha l. Expert Opin Biol Ther 2009; 9: 593-608.
24. Shimaoka M and Park EJ. Advances in understanding sepsis. Eue J Aneasthesiol 2008; 25: 146-153.